AI Article Synopsis
- The study aimed to assess the age and stage of breast cancer in patients at a tertiary care center in Karachi, Pakistan.
- A review of biopsy-proven breast cancer cases from 1994 to 2016 showed that the most common age for diagnosis was in the 30s, with nearly half of the cases diagnosed at stage 2 and less than 4% at stage 1.
- The findings indicate that breast cancer tends to be diagnosed at a younger age and more advanced stage in Pakistan compared to Western countries.
Article Abstract
Objective: To determine the age and stage of breast cancer in a tertiary care center in Karachi, Pakistan.
Methods: This retrospective, descriptive study was conducted at Breast Unit, Department of Surgery, Liaquat National Hospital Karachi, Pakistan. From 1994 to 2016 all biopsy-proven breast cancer patients were reviewed and their age and stage at presentation were noted .
Results: In the given time period 10, 018 patients with Breast cancer were registered. The most frequent age at diagnosis was in the fourth decade of life (28.51%). The majority of patients were diagnosed in stage 2 (47.26%) and only less than 4% were detected in stage 1. The stage of presentation did not differ between young and older age group of women.
Conclusions: Breast cancer is diagnosed at a younger age group in Pakistan, at least a decade earlier than the west and at an advanced stage, commonest being stage 2.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Identification of 8-(2-methyl phenyl)-9H-benzo[f]indeno[2,1-c]quinolin-9-one (C-5635020) as a novel and selective TGFβ RII kinase inhibitor for breast cancer therapy.
Biochem Biophys Res Commun
January 2025
Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Khalid University, Abha, Saudi Arabia. Electronic address:
Objective And Significance: Transforming growth factor-beta (TGF-β) plays a pivotal role in breast development by modulating tissue composition during the developmental phase. The TGFβ type II receptor (TGFβ RII) is implicated in breast cancer and represents a valuable therapeutic target. Due to the off-target side effects of many existing TGFβI/TGFβ RII inhibitors, a more targeted approach to drug discovery is necessary.
View Article and Find Full Text PDFExploring 1,2,3-triazole-Schiff's base hybrids as innovative EGFR inhibitors for the treatment of breast cancer: In vitro and in silico study.
Bioorg Chem
January 2025
Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Suez Canal University, Ismailia, Egypt. Electronic address:
EGFR inhibitors are a class of targeted therapies utilized in the management of certain tumor kinds such as NSCLC and breast cancer. Series of 1,2,3-triazole-Schiff's base hybrids were designed, synthesized, and estimated for their antitumor effect toward breast cancer cells, MCF-7 and MDA-MB-231. The safety and selectivity of the new compounds were tested using normal cell (WI-38).
View Article and Find Full Text PDFExpanding the Horizon of MRONJ Research in Breast Cancer Bone Metastasis Treatments.
J Clin Oncol
January 2025
Liangyu Mi, MD, Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Taiyuan, China, Shanxi Province Clinical Research Center for Dermatologic and Immunologic Diseases (Rheumatic Diseases), Taiyuan, China; James Cheng-Chung Wei, MD, Department of Allergy, Immunology & Rheumatology, Chung Shan Medical University Hospital, Taichung, Taiwan, Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan, Department of Nursing, Chung Shan Medical University, Taichung, Taiwan, Graduate Institute of Integrated Medicine, China Medical University, Taichung, Taiwan, Office of Research and Development, Asia University, Taichung, Taiwan; and Ke Xu, MD, Jinfang Gao, MD, Yalin Zhao, MD, and Liyun Zhang, MD, Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Taiyuan, China, Shanxi Province Clinical Research Center for Dermatologic and Immunologic Diseases (Rheumatic Diseases), Taiyuan, China.
High CXCL8 expression predicting poor prognosis in triple-negative breast cancer.
Anticancer Drugs
January 2025
Department of Oncology, Lianyungang Clinical College of Nanjing Medical University/The Affiliated Lianyungang Hospital of Xuzhou Medical University, Lianyungang, Jiangsu Province, China.
Triple-negative breast cancer (TNBC) is highly prone to early relapse and metastasis following standard treatment. CXCL8 is a key factor in tumor invasion and metastasis, but its role in TNBC prognosis and clinicopathological correlations remains poorly understood. This study investigated CXCL8 expression and its clinical significance in TNBC to develop a prognostic nomogram for guiding intensive treatment and follow-up strategies.
View Article and Find Full Text PDFThe Comparative Frequency of Breast Cancer-Related Lymphedema Determined by Perometer and Circumferential Measurements: Relationship with Functional Status and Quality of Life.
Lymphat Res Biol
January 2025
Ankara Bilkent City Hospital, Physical Medicine and Rehabilitation Hospital, Health Science University, Ankara, Turkiye.
The aim of this study was to comparatively determine the frequency of breast cancer-related lymphedema (BCRL) by using prospective monitoring with perometer and circumferential measurements in a group of patients who underwent breast cancer surgery. We also aimed to evaluate the relationship between volume changes and functional status and quality of life (QoL) in patients with breast cancer-related subclinical lymphedema. Patients who had unilateral breast cancer surgery for breast were assessed with circumferential and perometer, respectively, for volumes at baseline, 3rd-month, 6th-month, 9th-month, and 12th-month by the same physiotherapist.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!